Ricardo Blázquez‐Encinas

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Emilia Alors‐Pérez · 4 shared papers, 2021–2024 · strength 0.61
   • Paper Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. DOI 10.1186/s13046-023-02858-z↗
   • Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
   • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
2. Justo Pastor Castano · 4 shared papers, 2021–2024 · strength 0.61
   • Paper Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. DOI 10.1186/s13046-023-02858-z↗
   • Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
   • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
3. Andrea Mafficini · 3 shared papers, 2021–2024 · strength 0.43
   • Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
   • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
   • Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
4. Rita Teresa Lawlor · 3 shared papers, 2021–2024 · strength 0.43
   • Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
   • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
   • Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
5. Aldo Scarpa Scarpa · 3 shared papers, 2021–2024 · strength 0.43
   • Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
   • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
   • Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
6. Bruno Sáinz · 2 shared papers, 2021–2023 · strength 0.27
   • Paper Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. DOI 10.1186/s13046-023-02858-z↗
   • Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
7. Claudio Luchini · 2 shared papers, 2021–2024 · strength 0.26
   • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
   • Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗
8. Sabrina Gloria Giulia Testoni · 1 shared paper, 2025 · strength 0.22
   • Paper From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. DOI 10.1016/j.semcancer.2025.03.004↗
9. Riccardo Farinella · 1 shared paper, 2025 · strength 0.22
   • Paper From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. DOI 10.1016/j.semcancer.2025.03.004↗
10. Matteo Tacelli · 1 shared paper, 2025 · strength 0.22
    • Paper From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. DOI 10.1016/j.semcancer.2025.03.004↗
11. Giulia Peduzzi · 1 shared paper, 2025 · strength 0.22
    • Paper From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. DOI 10.1016/j.semcancer.2025.03.004↗
12. Daniele Campa · 1 shared paper, 2025 · strength 0.22
    • Paper From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. DOI 10.1016/j.semcancer.2025.03.004↗
13. Manuel Gentiluomo · 1 shared paper, 2025 · strength 0.22
    • Paper From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. DOI 10.1016/j.semcancer.2025.03.004↗
14. Eithne Costello · 1 shared paper, 2025 · strength 0.22
    • Paper From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction. DOI 10.1016/j.semcancer.2025.03.004↗
15. Corinne Bousquet · 1 shared paper, 2024 · strength 0.18
    • Paper The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. DOI 10.1038/s41417-024-00814-3↗
16. Iranzu González‐Borja · 1 shared paper, 2024 · strength 0.16
    • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
17. Antonio Viúdez · 1 shared paper, 2024 · strength 0.16
    • Paper Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable … DOI 10.1002/1878-0261.13658↗
18. Sonia Alcalá · 1 shared paper, 2021 · strength 0.09
    • Paper Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cance… DOI 10.1186/s13046-021-02153-9↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.